Optimizing Type 2 Diabetes Management in a Medically Complex Patient: A Case Report of a Patient with Type 2 Diabetes and HIV

Figures & data

Table 1 Baseline and Follow Up Laboratory Findings at 6 and 12 Months

Parameter and Laboratory Reference Range	Baseline	After 6 Months	After 12 Months
HBA1C (4.3–5.7%)	12.1	7.5	6.5
Random glucose (3.6–7.8 mmol/L)	14.6	5.9	6.6
Fasting C peptide (260–1728 pmol/L)	513	–	–
Creatinine (30.5–83.8 µmol/L)	103.7	67.1	81.6
Urea (3.57–17.85 mmol/L)	13.8	12.8	10
LDL in Diabetes (mmol/L)	5.1	2.8	2.7
HDL (mmol/)	1.0	1.6	1.7
Total cholesterol (mmol/L)	6.5	4.3	4.7
Triglycerides (mmol/L)	1.7	2.2	1.3
Albuminuria	0	Trace	0

Figure 1 Body weight trend over one year of follow-up.

Figure 2 HBA1C trend over one year of follow-up.

Figure 3 Direct costs of insulin and self-monitoring of blood glucose for families in low-income and middle-income countries.²

Notes: Data are from the World Health Organization (WHO Diabetes Country Profiles 2016) and are the typical supply costs for a family with one child with type 1 diabetes. *The amount of insulin required was assumed to be 18 vials of 100 IU/mL human insulin (or equivalent volume of 40 IU/mL). ^†Government provides insulin for free. ^‡Cost updated from previous data.

Abbreviation: SMBG, self-monitoring of blood glucose.

Klatman EL, Jenkins AJ, Ahmedani MY, Ogle GD. Blood glucose meters and test strips: global market and challenges to access in low-resource settings. Lancet Diabetes Endocrinol. 2019;7(2):150–160. doi:10.1016/S2213-8587(18)30074-3

 PubMed Web of Science ®Google Scholar